Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Inclusion Criteria:

PRE-REGISTRATION: Age >= 18 years and =< 45 years of age
PRE-REGISTRATION: Presence of lesion suspicious for benign breast disease on mammography and planned breast biopsy
PRE-REGISTRATION: Had a live birth =< 10 years prior to pre-registration
PRE-REGISTRATION: Pre-menopausal according to patient report and/or clinical determination
PRE-REGISTRATION: Provide written informed consent
PRE-REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance
PRE-REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research
PRE-REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research
REGISTRATION: Age >= 18 years and =< 45 years of age
REGISTRATION: Histological confirmation of benign breast disease (i.e., no evidence of DCIS or invasive cancer)
REGISTRATION: Registration must be completed =< 30 days after pre-registration biopsy performed for this study
REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 30 days prior to registration)
REGISTRATION: Platelet count >= 100,000/mm^3 (obtained =< 30 days prior to registration
REGISTRATION: Serum creatinine =< 2.0 mg/dl (obtained =< days prior to registration)
REGISTRATION: Negative pregnancy test done =< 14 days prior to registration
REGISTRATION: Willing to use contraception while on treatment
REGISTRATION: Provide written informed consent
REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance
REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research
REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research
REGISTRATION: Willing to return to enrolling institution for follow-up

Exclusion Criteria:

PRE-REGISTRATION: History of breast cancer including ductal breast carcinoma in situ (DCIS)
PRE-REGISTRATION: Received systemic treatment for any other cancer at any time
PRE-REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS) (no doses within =< 5 days prior to pre-registration and no more than eight doses within =< 30 days prior to pre-registration)
PRE-REGISTRATION: Currently taking other agents for the prevention of breast cancer
PRE-REGISTRATION: Currently taking anticoagulants
PRE-REGISTRATION: Contraindication for aspirin use
REGISTRATION: No research tissue collected during pre-registration biopsy performed for this study
REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) (NOTE: no doses within =< 5 days prior to registration and no more than four doses within =< 30 days prior to registration)
REGISTRATION: Co-morbid illnesses/conditions which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

REGISTRATION: Any contraindication to aspirin use including but not limited to:

Bleeding disorders (e.g., hemophilia)
Stomach or intestinal bleeding =< 6 months prior to registration
Known allergy to other non-steroidal anti-inflammatory drugs (NSAIDs)
REGISTRATION: Currently taking anticoagulants
REGISTRATION: Any malignancy requiring systemic therapy
REGISTRATION: Currently pregnant or planning to become pregnant in the next 90 days

REGISTRATION: Post-menopausal:

Prior bilateral surgical oophorectomy or
No menses for > 1 year with estradiol levels within postmenopausal range, according to institutional standard